-
MingMed Biotech’s Hong Kong IPO Signals Push for First-in-Class Drugs
•
Guangzhou-based MingMed Biotech has officially made an initial public offering (IPO) to the Hong Kong Stock Exchange (HKSE). CICC and Credit Suisse are acting as co-sponsors. Company OverviewThe innovation-driven pharmaceutical company is focused on the self-discovery and development of potential first-in-class (FIC) drugs. These drugs aim to address major unmet…
